April 22nd 2024
Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.
Tom Martens, MD, Talks about the Vision for CGM as Part of Primary Care for Type 2 Diabetes
June 18th 2021MOBILE study lead author Tom Martens, MD, talks about the inherent benefits of CGM for T2D patients on basal insulin treated in primary care and also the challenges to this vision of patient care.